Tusker Medical, Inc.  Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017  Page 1 of 70 A PROSPECTIVE,  MULTICENTER STUDY T O EVALUATE 
EFFECTIVENESS AND SA FETY OF LIDOCAINE IONTOPHORE SIS AND 
TYMPANOSTOMY TUBE PLACEMENT USING THE TULA 
IONTOPHORESIS AND TU BE DELIVERY SYSTEMS FOR  ADULTS  IN 
AN OFFICE  SETTING  (ADEPT ; ADult study to Evaluate Placem ent of 
tympanostomy Tubes in -office )
Study Product s: 
•TULA Iontophoresis System,
•2% Lidocaine  HCl/1:100,000 Epinephrine
•and TULA  Tube Delivery System
Study Phase:  Pre-Pivotal  
Protocol #:  CPR00 7003  
Revision: C 
IDE Number : G170002  
SPONSOR:  
Tusker Medical , Inc.  
155 Jefferson Drive , Suite 200  
Menlo Park, CA 94025  
USA  
MEDICAL MONITOR:  
This protocol contains confidential information for use by investigators participating in this 
study and should be maintained in a secure location . It should not be duplicated or made 
availa ble for review by any unauthorized person or firm . 
[STUDY_ID_REMOVED]
Tusker Medical, Inc.   Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 2 of 70 A PROSPECTIVE,  MULTICENTER STUDY T O EVALUATE 
EFFECTIVENESS AND SA FETY OF LIDOCAINE IONTOPHORE SIS AND 
TYMPANOSTOMY TUBE PLACEMENT USING THE TULA 
IONTOPHORESIS AND TU BE DELIVERY SYSTEMS FOR ADULTS IN 
AN OFFICE  SETTING  (ADEPT ; ADult study to Evaluate Placem ent of 
tympanostomy Tubes in -office ) 
 
 
Protocol Number: CPR007003  
 
Approved By:  
 
______________________________________________   _______________  
        Date  
 
 
 
______________________________________________   _______________  
       Date  
 
 
 
______________________________________________   _______________  
        Date  
 
 
 
______________________________________________   _______________  
        Date  
 
 
 
 
  

Tusker Medical, Inc.   Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 3 of 70 TABLE  OF CONTENTS  
 
TABLE OF CONTENTS  ................................ ................................ ................................ ....................  3 
1.0 INVESTIGATORS  ................................ ................................ ................................ ..........................  6 
2.0 STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .......  6 
3.0 INVESTIGATOR SIGNATURE PAGE ................................ ................................ ................................ .. 7 
4.0 LIST OF ABBREVIATIONS  ................................ ................................ ................................ ..............  8 
5.0 PROTOCOL SUMMARY  ................................ ................................ ................................ .................  9 
6.0 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ................................ ..............................  17 
6.1. CLINICAL PROGRAM OVERVIEW  ................................ ................................ ................................ .. 17 
6.2. CLINICAL AND TECHNOLOGY BACKGROUND  ................................ ................................ ..................  17 
7.0 STUDY DEVICES  ................................ ................................ ................................ ........................  19 
7.1. DEVICE DESCRIPTIONS ................................ ................................ ................................ ...............  20 
7.1.1.  IONTOPHORESIS SYSTEM  ................................ ................................ ................................ ...........  20 
7.1.2.  IONTOPHORESIS BASIC OPERATING PRINCIPLES  ................................ ................................ .............  25 
7.1.3.  TUBE DELIVERY SYSTEM (TDS)  ................................ ................................ ................................ ... 27 
8.0 STUDY DRUG ................................ ................................ ................................ ...........................  28 
      ................................ ...............  28 
9.0 TUSKER MEDICAL CLINICAL EXPERIENCE  ................................ ................................ .......................  30 
10.0 RISK AND BENEFIT ANALYSIS  ................................ ................................ ................................ ...... 30 
11.0 STUDY DESIGN  ................................ ................................ ................................ .........................  30 
11.1.  STUDY OBJECTIVE  ................................ ................................ ................................ .....................  30 
11.2.  OVERALL STUDY DESIGN – GROUPS AND ENROLLMENT  ................................ ................................ .. 31 
11.2.1.  ENROLLMENT LIMITS  ................................ ................................ ................................ ................  32 
11.3.  PRIMARY ENDPOINT RATIONALE  ................................ ................................ ................................ . 32 
11.4.  STUDY POPULATION  ................................ ................................ ................................ .................  34 
11.4.1 . DEFINITION OF ENROLLMENT  ................................ ................................ ................................ ..... 34 
11.5.  PRIMARY ENDPOINTS  ................................ ................................ ................................ ................  34 
11.6.  SAFETY ENDPOINT  ................................ ................................ ................................ ....................  36 
11.7.  SECONDARY ENDPOINTS  ................................ ................................ ................................ ............  36 
  ................................ ................................ ................................ ...........  36 
  ................................ ................................ .............................  36 
 ................................ ................................ .............................  36 
11.9.  INCLUSION CRITERIA  ................................ ................................ ................................ .................  37 
11.10.  EXCLUSION CRITERIA ................................ ................................ ................................ .................  37 
12.0 STUDY PROCEDURES  ................................ ................................ ................................ .................  39 
12.1.  INVESTIGATOR TRAINING  ................................ ................................ ................................ ...........  39 
12.2.  EVALUATION METHODS  ................................ ................................ ................................ ............  39 
12.2.1.  DIAGNOSIS (GROUP B) ................................ ................................ ................................ .............  39 
12.2.2.  CONCOMITANT MEDICATIONS  ................................ ................................ ................................ .... 40 
12.2.3.  CRANIAL NERVE PHYSICAL EXAM ................................ ................................ ................................  40 
12.2.4.  OTOSCOPY  ................................ ................................ ................................ ..............................  40 
12.2.5.  TYMP ANOMETRY  ................................ ................................ ................................ ......................  41 
12.2.6.  AUDIOMETRY  ................................ ................................ ................................ ..........................  41 
12.2.7.  ANESTHESIA EFFECTIVENESS  ................................ ................................ ................................ .......  41 
12.2.8.  TOLERABILITY (VAS)  ................................ ................................ ................................ .................  42 
 ................................ ................................ ..............................  42 
12.2.10.  VITAL SIGNS (GROUP B) ................................ ................................ ................................ ...........  43 

Tusker Medical, Inc.   Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 4 of 70 12.3.  SUBJECT RECRUITMENT AND INFORMED CONSENT ................................ ................................ .........  43 
12.4.  SCREENING EVALUATIONS  ................................ ................................ ................................ .........  44 
12.5.  PROCEDURE  ................................ ................................ ................................ ............................  44 
12.5.1.  VITAL SIGNS (GROUP B) ................................ ................................ ................................ ............  44 
12.5.2.  OTOSCOPIC EXAMINATION AND EAR PREPARATION  ................................ ................................ .......  44 
12.5.3.  EARSET SIZING  ................................ ................................ ................................ .........................  44 
12.5.4 . ANESTHETIC SOLUTION PREPARATION  ................................ ................................ .........................  45 
12.5.5.  EARSET PLACEMENT AND DRUG INSTILLATION  ................................ ................................ ..............  45 
12.5.6.  START OF IONTOPHORESIS  ................................ ................................ ................................ .........  45 
12.5.7.  ANESTHETIC SOLUTION AND RETURN ELECTRODE PATCH REMOVAL  ................................ .................  46 
12.5.8.  POST-IONTOPHORESIS ANESTHESIA EFFECTIVENESS (GROUP A) ................................ .......................  46 
12.5.9.  POST-IONTOPHORESIS ANESTHESIA EFFECTIVENESS (GROUP B) ................................ .......................  47 
12.5.10.  TYMPANOSTOMY TUBE PLACEMENT (GROUP B ONLY ) ................................ ................................ ... 47 
12.5.11.  CRANIAL NERVE EXAM ................................ ................................ ................................ .............  47 
12.6.  GROUP A FOLLOW -UP ................................ ................................ ................................ ..............  48 
12.7.  GROUP B FOLLOW -UP ................................ ................................ ................................ ..............  48 
12.8.  SUMMARY - STUDY EVALUATIONS , GROUP A ................................ ................................ ................  49 
12.9.  SUMMARY – STUDY EVALUATIONS , GROUP B ................................ ................................ ...............  49 
13.0 ASSESSMENT OF SAFETY  ................................ ................................ ................................ ............  50 
13.1.  ADVERSE EVENTS  ................................ ................................ ................................ .....................  50 
13.2.  SERIOUS ADVERSE EVENTS  ................................ ................................ ................................ .........  51 
13.3.  ADVERSE EVENT DEFINITIONS  ................................ ................................ ................................ .... 51 
13.4.  ADVERSE EVENT CLASSIFICATION  ................................ ................................ ................................  52 
13.5.  SAFETY MONITORING  ................................ ................................ ................................ ...............  54 
13.6.  DEVICE MALFUNCTIONS  ................................ ................................ ................................ ............  54 
14.0 STATISTICAL METHODS  ................................ ................................ ................................ .............  55 
14.1 . SUBJECT DISPOSITION  ................................ ................................ ................................ ...............  55 
14.2.  GENERAL STATISTICAL METHODS  ................................ ................................ ................................  55 
14.3.  GROUP A – STATISTICAL METHODS  ................................ ................................ .............................  56 
14.3.1.  RANDOMIZATION & BLINDING  ................................ ................................ ................................ ... 56 
14.3.2.  ANALYSIS SETS ................................ ................................ ................................ .........................  57 
14.3.2 .1.M ODIFIED INTENTION TO TREAT (MITT) ................................ ................................ .....................  57 
14.3.2.2.P ER PROTOCOL SET ................................ ................................ ................................ .................  57 
14.3.2.3.S AFETY ANALYSIS SET ................................ ................................ ................................ ..............  57 
14.3.3.  PRIMARY ENDPOINT ANALYSIS  ................................ ................................ ................................ ... 57 
14.3.4.  SAFETY ANALYSIS  ................................ ................................ ................................ .....................  58 
 ................................ ................................ ..............................  58 
14.4.  GROUP B – STATISTICAL METHODS  ................................ ................................ .............................  58 
14.4.1.  ANALYSIS SETS ................................ ................................ ................................ .........................  58 
14.4.1.1.F ULL ANALYSIS SET (FAS)  ................................ ................................ ................................ .........  58 
14.4.1.2.P ER PROTOCOL SET ................................ ................................ ................................ .................  58 
14.4.1.3  SAFETY ANALYSIS SET ................................ ................................ ................................ ...............  59 
14.4.2.  PRIMARY ENDPOINT ANALYSIS  ................................ ................................ ................................ ... 59 
14.4.3.  SAFETY ANALYSIS  ................................ ................................ ................................ .....................  59 
 ................................ ................................ ..............................  60 
      ................................ ................................ ..... 61 
14.6.  HANDLING DROP OUTS OR MISSING DATA ................................ ................................ ...................  62 
14.7.  MULTIPLICITY ADJUSTMENT  ................................ ................................ ................................ .......  62 
15.0 ETHICS /PROTECTION OF HUMAN SUBJECTS  ................................ ................................ ..................  63 
15.1.  SUBJECT CONFIDENTIALITY  ................................ ................................ ................................ .........  63 
16.0 PREMATURE TERMINATION OR WITHDRAWAL  ................................ ................................ ..............  63 

Tusker Medical, Inc.   Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 5 of 70 16.1.  SUBJECT STOPPING CRITERIA  ................................ ................................ ................................ ...... 63 
  ................................ ................................ ................................ ........  64 
17.0 INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ................................ . 65 
18.0 SPONSOR  ................................ ................................ ................................ ................................  65 
19.0 MONITORING  ................................ ................................ ................................ ..........................  66 
20.0 INVESTIGATIONAL PRODUCT ACCOUNTABILITY  ................................ ................................ ..............  66 
21.0 DEVIATIONS  ................................ ................................ ................................ ............................  66 
22.0 DATA HANDLING AND RECORD KEEPING  ................................ ................................ ......................  67 
22.1.  SOURCE DATA AND CASE REPORT FORMS  ................................ ................................ ....................  67 
22.2.  DATA QUALITY ASSURANCE  ................................ ................................ ................................ .......  67 
22.3.  RECORD RETENTION  ................................ ................................ ................................ .................  67 
23.0 PUBLICATION POLICY  ................................ ................................ ................................ ................  67 
24.0 REFERENCES  ................................ ................................ ................................ ............................  68 
 
 
 
TABLES  
 
 .............................  29 
Table 2. Schedule of Evaluations – Group A  ................................ ................................ ..........  49 
Table 3. Schedule of Evaluations – Group B  ................................ ................................ ...........  50 
Table 4. Table of Adverse Event Severity  ................................ ................................ ...............  53 
Table 5. Table of Adverse Event Causality  ................................ ................................ .............  53 
Table 6. Table of Hearing Threshold Change (Worsening) Classification  .............................  54 
 
 
FIGURES  
 
. ..........  22 
 ................................ ................................ ................................ . 23 
Figure 3. Return Electrode Patch  ................................ ................................ .............................  24 
Figure 4. Ear Plug Sizers  ................................ ................................ ................................ .........  24 
Figure 5. Current Ramp Profile  ................................ ................................ ...............................  26 
Figure 6. Schematic of Iontophoresis of the TM  ................................ ................................ ..... 26 
Figure 7. Tusker Medical Tympanostomy Tube  ................................ ................................ ...... 27 
Figure 8. Tube Delivery System  ................................ ................................ ..............................  27 
Figure 9. Visual Analogue Scale (not shown to scale)  ................................ ............................  42 
 ................................ ................................ .......................  42 
 
  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 6 of 70 1.0  INVESTIGATORS  
A list of Investigators is provided with the Investigator’s  Information  and will be submitted 
to the FDA and IRB.   
 
Statements of Qualifications:  
Qualifications of investigators are provided in the Investigator  Information  and will be 
submitted to the FDA and IRB.  
 
2.0 STATEMENT OF COMPLIA NCE  
This study will be conducted in accordance with any specific provisions of the associated 
Institutional Review Board(s) (IRBs)  and 21 CFR Part s 812 and 312. This study will be 
conducted in  accordance with the ethical principles that have their origin in the Declaration 
of Helsinki and that are consistent with Good Clinical Practice (GCP) , ISO 14155 and the 
applicable national and regional regulatory requirements . Specifically, this study wi ll be 
guided by the ethical principles of The Belmont Report, the Declaration of Helsinki, and 
the International Conference for Harmonization Good Clinical Practice (ICH -GCP) .  
  
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 7 of 70 3.0  INVESTIGATOR SIGNAT URE PAGE  
I acknowledge receipt of protocol and confirm I have read and understood its contents and 
agree to fulfill my obligations as described herein . I will ensure that the study is conducted 
in compliance with the protocol and all applicable regulatory requirements.  
 
 
 
________________________________ ________ _______________   
INVESTIGATOR (Print N ame)  
 
 
________________________________ _______________________  
INSTITUTION  
 
 
________________________________ _______________________  
ADDRESS  
 
 
________________________________ _______________________  
SIGNATURE  
 
 
________________________________ _______________________  
DATE  (DD/MMM /YYYY ) 
  
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 8 of 70 4.0  LIST OF ABBREVIATIO NS     
AE    Adverse Event  
AOM    Acute Otitis Media  
CFR    Code of Federal Regulations  
CRF    Case Report Form  
CTA    Clinica l Trial Agreement  
dB    Decibels  
DC    Direct Current  
DIPS    Device Initiated Pause Sequence  
EMLA    Eutectic Mixture of Lidocaine  HCl and Prilocaine  
ENT    Ear, Nose and Throat  
FAS    Full Analysis Set  
FDA    Food and Drug Administration  
FPS-R   Faces Pain Scale - Revised  
GCP    Good Clinical Practice  
HCl   Hydrochloride  
ICH    International Conference for Harmonization  
IDE   Investigational Device Exemption  
IFU   Instructions For Use  
IND   Investigational New Drug  Application  
IO    In Office  
IPS   Iontoph oresis System  
IRB   Institutional Review Board  
ISO   International Organization for Standardization  
LCD    Liquid -Crystal Display  
MedRA    Medical Dictionary for Regulatory Activities  
mITT    Modified Intent to Treat  
MTT    Myringotomy with Tympanostomy Tube  
NSR    Non-Significant Risk  
OME    Otitis Media with Effusion  
OR   Operating Room  
PSA    Pressure -Sensitive Adhesive  
SAE    Serious Adverse Event  
SD    Standard Deviation   
TDS    Tube Delivery System  
TM   Tympanic Membrane  
TT    Tympanostomy Tube  
UADE    Unanticipated Adverse Device Effect  
VAS    Visual Analogue Scale  
  
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 11 of 70 audiometry will be conducted.  If ther e are unresolved device, procedure 
or drug -related adverse events at the 3 -day follow -up visit, a 12 -day 
follow -up visit is required.  
 
Group B will consist of 30 evaluable  adults  age 18 years  or greater  who 
require unilateral or bilateral tube insertion enrolled at up to 9 centers in 
the US.  Otologic examination, cranial nerve physical exam, tympanometry 
and audiometry will be conducted at the screening visit.     
 
Group B subjects will receive active lidocaine iontophoresis and will have 
tubes placed using the TDS  in all ears indicated for tube placement .  The 
subject will rate the pain upon TDS  tube insertion using the VAS , and the 
pain score will be  compared to a performance goal.   
 
 
Vital signs (diastolic and systolic blood pressure, heart rate, 
respiratory rate and pulse oximetry ) will be monitor ed prior to and  
periodically up to 1 hour following iontophoresis.  A follow -up at 3 weeks 
is required for all subjects, at which point otologic examination, cranial 
nerve physical exam, tympanometry and audiometry will be conducted.  
  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 17 of 70  
6.0  BACKGROUND INFORMAT ION AND SCIENTIFIC R ATIONALE  
6.1.  Clinical Program Overview  
Tusker Medical has developed a suite of technologies designed to enable in -office 
placement of tympanostomy tubes in pediatric and adult patients. This protocol 
(CPR007003) describes two groups of adult subjects, each designed to demonstrate a 
particular a spect of the investigational technology.   
 
 
 
 
 
Although this study is conducted in adult subjects and the investigational technology will 
ultimately be available for both adult and pediatric pati ents, it is anticipated that the 
majority of use will be in the pediatric population.  Therefore, Section 6.2  is focused on 
the ultimate use of the product in the pediatric population.  
 
6.2. Clinical and Technology Background  
 
Otitis media (inflammation of the middle ear) is the most frequent diagnosis in sick children 
visiting pediatrician offices. Seventy -five percent of children experience at least one 
episode of otitis media by their third year.3  
 
Otitis media has several variations, in cluding acute otitis media (AOM) and otitis media 
with effusion (OME). AOM is characterized  by acute signs and symptoms of middle ear 
inflammation  or infection .  OME is characterized by  the presence of fluid in the middle ear 
with or without signs or sympt oms of acute ear infection.  The highest incidence of AOM 
occurs between six and 24 months of age and declines until a small reversal is seen between 
five and six years of age, at the time of school entry.4 There tends to be a higher incidence 
of OME in yo unger than in older children, because the Eustachian tube in younger children 
is shorter, narrower, and more horizontal  and the immune system is less developed  
compared to older children or adults . There is also increased incidence of OME associated 
with c raniofacial anomalies, cleft palate, and Down syndrome.  Middle ear effusion can 
result in temporary conductive hearing loss and negatively impact a child’s cognitive, 
language, and emotional development.   
 
More than 750,000 tympanostomy tube procedures  are performed in children younger than 
age 18  annually in the US to address recurrent AOM or OME , making it one of the most 
common surgical procedures performed in children.5 By age 3, almost 7% of all children 
will have tympanostomy tubes.1 Over 75% of tympanostomy tube procedures in the US are 
performed for children 12 years or younger, with 58% of tube procedures for  children less 
than 5 years of age.5  Over 95% of tympanostomy tube insertion procedures in children are 
performed in the operating room (OR) under general anesth esia.5  
 
The typical Myringotomy with Tympanostomy Tube placement (MTT) procedure in a child 
involves th e following sequence of events:  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 18 of 70 • The child fasts from the evening before the procedure and is brought to the 
hospital or ambulatory surgery center . 
• Premedication with oral midazolam may be provided to calm the child prior to 
parental separation.6 
• After general anesthesia is attained, prophyla ctic analgesia to address post -
operative pain such as rectal acetaminophen  or intranasal fentanyl is typically 
provided.7 
• Cerumen clearance is performed.  
• Using a myringotomy blade, an adequately sized myringotomy incision is then 
made, typically in the ant eroinferior portion of the tympanic membrane.8,9  
• Fluid may be removed from the middle ear space using suction.  
• Using alligator forceps, the tympanostomy tube is manipulated and tucked into 
the myringotomy incision.  
• Minor adjustments are then often perform ed using standard otologic 
microinstruments, such as a Rosen needle or alligator forceps, to achieve 
optimal  tube position.10  
• Multiple attempts to place the tube may be required in a considerable number 
of cases.8  
 
In adult patients and older children, tympanostomy tubes can be placed in an office setting 
using a variety of local anesthesia options  although none are indicated for anesthesia of the 
ear drum . Phenol (carbolic acid) is often used to cause a partial thickness chemical burn 
with tissue necrosis, which leads to localized anesthesia of the TM.11 Other anesthetics, 
such as EMLA cream (Eutectic Mixture of Local Anesthetics, lidoc aine 2.5% and 
prilocaine 2.5%) , lidocaine HCl injections and Bonain’s Solution (cocaine hy drochloride, 
menthol, phenol)  and tetracaine injections are used less frequently.12,13,14  None of the local 
anesthetics employed in adults are regularly used with small children,  as they are all 
associated with discomfort or a lengthy onset incompatible with pediatric use.   
 
There are several potential advantages to providing otolaryngologists, or Ear, Nose and 
Throat ( ENT ) surgeons , with technology that enables in -office tube placement in pediatric  
patients. The perioperative risks associated with the general anesthesia required for tube 
placement in the OR can be avoided with an office -based procedure. General anesthetic 
complicatio ns occur at measurable rates ranging between 12.6% and 18% in tube 
procedures in children.15,16 Although serious adverse effects  of general anesthesia during 
tube procedures are uncommon , they can be severe  including  laryngospasm, airway 
obstruction, desatur ation, dysrhythmia and post -operative vomitin g requiring treatment . 
 
In addition, t here is an increasing interest in gaining a better understanding of  the potential 
for neurodevelopmental impact of general anesthesia in small children.  A growing body 
of l iterature suggest s a linkage between general anesthesia exposure and 
neurodevelopmental impact, though it remains difficult to separate the post -general 
anesthesia outcomes from the underlying condition for which the child underwent surgery. 
One study show ed that  children who received general anesthesia before age 3 years were 
approximately 1.9 times as likely as controls to show language disability and 1.7  times as 
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 20 of 70 the prior generation of the device.  
 
 
 
 
 
 
 
 
Tusker Medical , Inc. has a Tube Delivery System intended to provide a means to create a 
myringotomy with insertion of a preloaded tympanostomy tube.  The design and operation 
of the TDS is intended to standardize the surgical approach to tympanostomy tube 
placement whereby upon actuation of the TDS, a myring otomy is created and a Tusk er 
Medical tympanostomy t ube is placed nearly simultaneously (within 500 ms). The TDS 
device combines myringotomy creation and tube insertion into one straightforward 
procedure step, thus avoiding the need to pass an exposed surgical blade though the ear 
canal of an awake  and mobile  patient.   
 
 
 
 
 
 
7.1. Device Description s 
7.1.1.  Iontophoresis System  
Iontophoresis uses low -level electric  current to direct  movement of drug ions into tissue 
through skin or mucosal surfaces.  
 
 The IPS employs a low -level electric current to transport 
the ionic drug, and may be performed unilaterally or bilaterally. The IPS is battery -powered  
and delivers 6.4mA -minutes of charge at a current of 0.8 mA (max imum ) to each channel .  
 
The IPS  is a single use device and consists of three components: an Iontophoresis Control 
Unit, Iontophoresis Earsets and a Return Electrode Pat ch. For bilateral drug delivery, two 
Iontophoresis Earsets are required. Accessories to the Iontophoresis System include a 
Syringe and Earset Siz ers. All components of the IPS  are provided non -sterile and no 
sterilization is required . All patient contact m aterials have been assessed for  
biocompatibility per ISO 10993. Iontophoresis with the IPS may be performed unilaterally 
or bilaterally, and bilateral iontophoresis may be performed either sequentially or 
simultaneously.  
 
• The Earset Sizers  are used to dete rmine the Earset size that best fits the patient’s 
anatomy. They are color -coded to correspond to each Earset size. Consecutive sizes are 
mounted at each end of a handle and labeled with a size number (Size 1 through Size 
6). They are a reusable accessory required to determine the Earset size for the ear canal 
requiring treatment.  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 21 of 70  
• The Earset  includes a n Ear Plug with Pressure -Sensitive Adhesive (PSA) attached to a 
handle, an integrated fill system, a n electrical connector , and an integrated ear electrode 
through which electrical current is delivered to the drug solution. The integrated fill 
system allows for the administration of drug solution with the electrode in situ for the 
initial fill of the external ear canal and for the intra -procedure delivery of a dditional 
drug solution to the external ear canal, as needed. Multiple Earset  sizes are available to 
accommodate variation in patient anatomy  and are color -coded to correspond to the 
Earset Sizers.  The range of ear plug sizes is appropriate for bo th pediat ric and adult 
patients . 
 
• The Control Unit  provides two independent channels of electrical current to the 
solution in the ear canal and to a single shared return electrode  patch . The Control Unit 
monitors and delivers a fixed amount of charge and alerts the operator when current 
delivery is complete.  
 
• The Return Electrod e Patch  attaches to the patient’s skin at a location remote from 
the ears to complete the electrical circuit a nd is connected to the Earset  and Control 
Unit via the return electrode snap.  
 
• The Syringe  is a single use device that allow s for administration of drug solution  
through the Earset  into the ear canal.  
 
Iontophoresis Control Uni t 
 
 
 
 
The Control Unit  provides two independent 
channels of electrical current. It is connected to one or two Earsets  and the Return Electrode 
Patch via the electrical connectors and return electrode snap, respectively .  The Control 
Unit can deliver current to a patient’s left and right ears sequentially or simultaneously, if 
desired. The Control Unit includes embedded software that delivers and regu lates both 
current and accumulated charge and alerts the operator when current delivery is complete. 
 
  
 
The user interface with the Control Un it consists of two push buttons  and a visual indicator 
of cycle progress (progress bars) .  Each push button is used to independently operate one 
Earset . Each push button can start, pause or resume current to one Earset . Push buttons are 
color coded (Yellow  and Blue) to identify the Earset  side they control . The progress bars   
are used to monitor iontophoresis progress and alert the operator of various devi ce states.  
 
 
 
If the Reduce feature is used by the operator, the device tracks overall charge, ensuring 
total charge/dose delivered remains the same as the prior generation of the device.    

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 23 of 70 The Earset  also includes an integrated ear electrode . The integrated ear electrode is used to 
deliver positive DC electrical cur rent to the administered drug.  
 
  
 
 
 
 
 
Return Electrode Patch  
 
The Return Electrode Patch ( Return Electrode ) shown in Figure 3 , attaches to the patient’s 
skin, g enerally on the arm or back, to complete the electrical circuit. The Return Electrode 
contains a hydrogel, which contacts and adheres to the patient’s skin. The Return Electrode 
acts as a cathode. The Return Electrode is connected to the System Cable of th e Control 
Unit.  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 30 of 70  
9.0   TUSKER MEDICAL  CLINICAL EXPERIENCE   
 
 
 
 
 
 
 
 
 
 
The Investigator’s  Brochure (CIB007001)  includes  a complete summary of the prior 
clinical data  and the specific device generations used for each study . 
 
10.0 RISK AND BENEFIT ANA LYSIS  
A description of risks and an analysis of risk versus benefit for subjects undergoing 
iontophor esis with tube placement (Group B) is presented in the Investigator’s Brochure 
CIB00700 1.  Group A subjects consist of healthy adult volunteers.  There are no benefits 
to healthy volunteers. However, the information collected will provide a foundation for the 
development of future applications and technology.  
 
11.0  STUDY DESIGN  
11.1. Study Objective  
Prior clinical trial experience has provided preliminary  safety and effectiveness of in -office 
tympanostomy tube placement in children using the T usker Medical  TULA Iontophoresis 
and Tube Delivery Systems. The objective s of this study are two-fold:  
 
1) to determine  if active lidocaine iontophoresis is superior to sham lidocaine 
iontophoresis in providing anesthesia to the tympanic membrane, and  
 
2) to evaluate tolerability  and safety of tympanostomy tube (TT) placement in adults  
following local anesthesia in a physician’s clinic setting . 
 
This study will co nsist of two independent Groups  (Group A and Group B ).  Each group 
has its own primary endpoint, both of which must pass the statistical test for the overall 
study to be considered successful and to meet the study objectives. In addition, safety will 
be evaluated by review of the occurrence of adverse events.  
 
The data from this study will provide evidence  that the inve stigational system will provide 
anesthesia sufficiently effective for the placement of tympanostomy tubes.   
 
 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 31 of 70 11.2. Overall Study Design – Groups and Enrollment  
This study is a  prospective, multicenter study to evaluate effectiveness and safety of 
lidocaine iontophoresis and tympanostomy tube placement using the TULA iontophoresis 
and tube delivery systems for adults in an office setting . 
 
This study wi ll consist of two independent Groups  (Group A and Group B ).  Each Group 
has its own primary endpoint, each of which must pass the statistical test for the overall 
study to be considered successful.   The two Gro ups may be enrolled in parallel, and 
investigational sites may enroll subjects in Group A alone, Group B alone, or both Groups.  
 
Group A will consist of 40 healthy adult subjects aged 18-50 with evaluable data , enrolled 
at two investigational centers in th e US. Otologic examination, cranial nerve  physical  
exam, tympanometry and audiometry  will be conducted at the screening visit.     
 
Group A subjects will be randomized to receive unilateral treatment (1 ear) with either 
active lidocaine iontophoresis or sham lidocaine iontophoresis.  The sham iontophoresis 
procedure will be identical to the active lidocaine iontophoresis, with the exception that 
the iontophoresis channel will not be activated (ie, the same drug solution will be applied 
to ears in both arms ).  
  
 
After the completion of the iontophoresis, the tympanic membrane will be touched with a 
dull otologic probe to test anesthesia  effectiveness .   The touch to the TM will slightly 
deflect the TM and allow for an assessment of anesthesia effectiveness. The touch is 
referred to as a ‘tap’  throughout the protocol .  
 
 
The subject will rate the level of pain using t he Visual Analogue Scale  (VAS ) 
after the tap.   
 Investigators and subjects will be blinded to treatment 
assignment.  
 
A follow -up at 3 days  post-procedure  is required for all subjects, at which point otologic 
examination, cranial nerve exam, tympanometry and audiometry will be conducted.  If 
there are unresolved device, procedure or drug -related adverse events at the 3 -day follow -
up visit, a 12-day follow -up visit is required.  
 
Group B will consist of 30 adults  18 years or older  who require unilateral or bilateral tube 
insertion, enrolled at up to 9 centers in the US.  Otologic examination, cranial nerve 
physical exam, tympanometry  and audiome try will be conducted at the screening visit.     
 
Group B subjects will receive active lidocaine iontophoresis and TDS -mediated tube 
placement in all ears that require tube insertion.  The VAS  score will be collected after  
any manipulations required to place the tube so that the pain score fully reflects the 
activities required to place the tube. VAS  score will be collected for each ear undergoing 
tube placement. If a subject discontinues iontophoresis or the procedure prio r to tube 
placement with the TDS, a VAS  score will be collected  for the attempted procedure . The 
pain score will be  compared to a fixed performance goal.  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 32 of 70  
 
 
 
 
 
 
 
 
 
 
 
   
 
Vital signs (diastolic and systolic blood pressure, heart rate, respiratory rate  and pulse 
oximetry) will be monitored 15 minutes  and immediately  prior to  iontophoresis, 
immediately following the iontophoresis , following tube placement, 30 minutes and 60  
minutes  after completion of iontophoresis  for all Group B subjects.  
 
A follow -up at 3 weeks is required for all subjects, at which point a n otologic examination, 
cranial nerve exam, tympanometry and audiometry will be conducted.  
 
11.2.1.   Enrollment Limits  
Group A: Group A consists of 2 sites. E ach site may enroll no greater than 70% of Group 
A subjects.  
 
Group B: Group B consists of up to 9 sites. Each site may enroll no greater than 3 0% of 
Group B subjects.  
 
11.3. Primary Endpoint Rationale  
Group A:  Anesthesia Effectiveness (Subject -Reported)  
 
In Group A, active lidocaine iontophoresis will be compared to sham lidocaine 
iontophoresis  (ie, lidocaine in the ear canal but without activating the iontophoresis unit for 
that channel).  After iontophoresis/ sham treatment is complete, the subject will use the VAS  
to rate the pain associated with a single tympanic membrane tap using a standardized blunt 
otologic probe. The VAS  was selected because it is a validated self -report pain instrument 
commonly used in research settings with adults  (reviewed in Jensen and Karoly) .34  The 
VAS is validated for use in subjects 8 years of age and old er (reviewed in Stinson et al 
(2006).35  The VAS  consists of  a 10 centimeter (cm) line with a statement at each end 
representing the extreme limits of pain intensity (“No pain” to “ Worst possible  pain”).  The 
subject reports their pain intensity by making a mark along the line and the line is measured 
to convert the subject response to numeric score (0 -10 in centimeters) . 
 
 
 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 34 of 70 cut points for pain severity as no pain at 0 to 4 mm, mild pain 5 to 44 mm,  moderate pain 
45 to 74 mm and severe pain 75 to 100mm. Altogether, the literature reports show 
remarkable consistency for the experimentally -determined cut point b etween mild and 
moderate pain.  
 
Prior TULA in office tube delivery study results indicate that tolerability scores are 
anticipated to be in the mild range. Therefore, it is reasonable to set a performance goal to 
be superior to (less painful than) moderate  pain.  Using the VAS, Tusker will demonstrat e 
superiority to a score of 4. 5cm (or 45mm) , based on Jensen’s determined cut point of 45mm 
for adult VAS scores, showing that the pain associated with in -office tube insertion in adult 
subjects is mild.    
 
11.4. Study Population  
Group A will consist of 40 healthy adult volunteers and Group B will consist of 30 adults 
indicated for  tympanostomy tubes in one or both ears.  The study may enroll up to 85 
subjects to achieve 40 subjects with evaluable data in Group A and 30 subjects with 
evaluable data in Group B, a llowing for approximately 15 screen failure  or withdrawn 
subjects . 
 
11.4.1.  Definition of Enrollment  
All subjects who consent for participation in the study are considered en rolled.  Subjects 
who do not meet eligibility criteria are considered screen failures.  Section 14.0 Statistical  
Methods provides f urther definition of subjects included in the analysis sets.  
 
11.5. Primary Endpoint s 
There are two primary endpoint s for the study , one for Group A and one for Group B .  Both 
primary endpoints must be achieved for the trial to be considered successful.   
 
Primary endpoint for Group A:  
 
Anesthesia Effectiveness : subject -reported pain score elicited by tympanic membrane ta p 
following active lidocaine iontophoresis compared to sham lidocaine iontophoresis using 
the VAS .    
 
Each Group A subject will each have a VAS  score .   If a subject in Group A discontinues 
iontophoresis prior to the TM tap assessment or declines  the TM t ap assessment , the subject 
will provide a pain score for the attempted procedure and will be  included in the analysis 
of the primary endpoint .  
 
 
 
Reasons for discontinuation will be documented  and presented in the clinical 
study report.    
 
Randomization will assign subject s to either unilateral active lidocaine iontophoresis or 
unilateral sham lidocaine iontophoresis treatment. Both the subject and the investigator 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 35 of 70 performing the taps will be blinded  as to treatment assignment . Blinding is further 
described in Section s 12.5.5 and 14.3.1 . 
 
A single tap will be performed  on the treated (or sham -treated) ear using a standardized 
dull otologic probe on the anterior part of the tympanic membrane.   
   
 
Primary endpoint for Group B:  
 
Tube Placement Tolerability:  Subject -reported pa in score following TDS tube 
placement using the VAS . 
 
Group B subjects will each have a single subject -level VAS  score that reflects the pain 
associated with tube insertion ; if both ears are treated the highest score of the two ears will 
serve as the subje ct-level score .  The statistical test for the primary endpoint is a hypothesis 
test comparing mean VAS  score  to a performance goal of 4.5, as described in Section 11.3.  
 
Group B subjects may require unilateral or bilateral tubes  and will receive active lidocaine 
iontophoresis and tube placement using the TDS in each ear that requires a tube insertion.   
 
 
 
 
  
 
  
  
 
   
 
The VAS  score will be collected after  any manipulations required to place the tube so that 
the pain score fully reflects the activities required to place the tube.  A VAS  score will be 
reported for each ear undergoing tube placement, and the highest (worst) pain reported by 
the subject will be  used as the unit of analysis.  
 
If a subject in Group B discontinues iontophoresis or tube placement, the subject will 
provide a VAS pain score for the attempted procedure .  
 
 
 
 
 
 
 
 
Reasons for discontinuation will be documented and presented in the 
clinical study report.  
 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 36 of 70 11.6. Safety Endpoint  
Safety: The occurrence of all adverse events, by subject. The totality of the safety data 
will be summarized and presented. Safety events will be reported for all subjects in which 
the lidocaine solution was introduced into the ear (see Section 14.2.3), and  will be  
reported for  the following time intervals : 
 
• Events occurring during  the procedure visit  
• Events occurring between the procedure through the subject’s final  follow -up visit  
 
Safety data will be presented separately as follows:  
 
• Group A  
• Group B  
 
11.7.     Secondary Endpoints  
There are no formal tests of hypotheses for secondary endpoints in either Group A or Group B.  
 
   
 
  
  
 
 
 
  
  
  
  
 
 
  
 
  
 
 
  
 
  
 
 
  
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 37 of 70   
 
  
  
 
 
 
11.9.  Inclusion Criteria   
Group A: At least one ear must meet ear -specific eligibility criteria.  
Group B: Each ear indicated for tube placement must meet ear -specific eligibility criteria.  
 
Group A:  
 
1. Healthy adults, 18 -50 years  old at time of consent   
2. Subject is able and willing to comply with the protocol and attend all study visits  
3. Subject is able and willing to provide informed consent  
4. Subjects with air conduction hearing thresholds of 25 dB HL or better at standard 
frequencies up to 2000 Hz, and 45 dB or better at 4000 Hz.  
5. Subject is a ble to read and understand English  
 
 
Group B:  
 
1. Adults at least 18 years of age at time of consent  
2. Indication for tympanostomy tube insertion per Clinical Practice Guideline,40 or 
indica ted for tympanostomy tube insertion tube insertion due to barotrauma or 
Eustachian tube dysfunction per AAO -HNS Clinical Indicators41  
3. Subject is able and willing to comply with the protocol and attend all study visits  
4. Subject is able and willing to provide informed consent.  
5. Subject is able to read and understand English.  
 
11.10.   Exclusion Criteria  
Group A:  
 
1. Pregnant or lactating females.  
2. Prior ear iontophoresis procedure experience.  
3. Subjects with conductive hearing loss.  
4. Subjects with history of sensitivity or allergic reaction to lidocaine HCl, tetracaine, 
epinephrine, or any hypersensitivity to local anesthetics of the amide type, or any 
component* of the anesthetic drug formulation .  
 
*Subjects  with a known hypersensitivity to methylparaben and /or propylparaben 
(preservatives used in lidocaine HCl formulations), or to their metabolite para amino 
benzoic acid (PABA), or other components including potassium metabisulfite, sodium 
metabisulfite, ededate disodium or citric acid.  
 
5. Familial history of insensitivity to lidocaine or other local anesthetics of the amide 
type.  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 38 of 70 6. Significantly atrophic, retracted, bimeric, monomeric or atelectatic tympanic 
membrane . 
7. Perforated tympanic membrane . 
8. Subjects with known history of ear surgery or TM condition that h as the potential to 
affect the sensitivity of the TM (ex. prior tympanostomy tube insertion)  
9. Otitis externa . 
10. Damaged/denuded skin in the auditory canal . 
11. Subjects with electrically sensitive support systems (pacemakers, defibrillators, etc.) . 
12. Cerumen impact ion resulting in a significant amount of cleaning required to visualize 
the tympanic membrane . 
13. Evidence of Otitis Media at day of procedure, or within the past three (3) months prior 
to procedure.   
14. Other conditions that would preclude performing the study procedure including ear 
plug incompatibility.  
15. Health conditions that, in the opinion of the investigator, would present undue risk to 
the subject, based on device/anesthetic drug product label warni ngs and precautions .  
 
Group B:  
 
1. Significantly atrophic, retracted  or retraction pocket at location of tube placement , 
bimeric, monomeric or atelectatic tympanic membrane . 
2. Perforated tympanic membrane . 
3. Otitis externa . 
4. Hemotympanum.  
5. Damaged/denuded skin in the auditory canal.  
6. Cerumen impaction resulting in a significant amount of cleaning required to visualize 
the tympanic membrane potentially causing abrasion or irritation to the external ear 
canal . 
7. Notable ear discomfort experienced during audiologic or ot oscopic exami nation . 
8. Anatomy that precludes sufficient visualization of and access to the tympanic 
membrane . 
9. Anatomy that necessitates tympanostomy tube placement in the posterior half of the 
tympanic membrane ). 
 
General Exclusion Criteria  
 
10. Pregnant or lactating females.  
11. History of sensitivity or allergic reaction to lidocaine HCl, tetracaine, epinephrine, or 
any hypersensitivity to local anesthetics of the amide type, or any component * of the 
anesthetic drug formulation . 
 
*Subjects  with a known hypersensitivity to methylparaben and/or propylparaben 
(preservatives used in lidocaine HCl formulations), or to their metabolite para amino 
benzoic acid (PABA), or other components including potassium metabisulfite, 
sodium metabisulfite, ede date disodium or citric acid.  
 
12. Familial history of insensitivity to lidocaine or other local anesthetics of the amide 
type.  
13. Electrically sensitive  medical  support systems ( eg, pacemakers, defibrillators, 
cochlear implants )  
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 39 of 70 14. Other conditions that would pre clude performing the study procedure including 
iontophoresis system ear plug incompatibility.  
15. Health conditions that, in the opinion of the investigator, would present undue risk to 
the subject, based on device/anesthetic drug product label warnings and pr ecautions  
 
If a previously -determined eligible  subject presents on the procedure day with a change in 
condition , such as an acute ly infected  ear, the investigator may use clinical  judgment to 
determine whether the condition as presented precludes performin g the study procedure  
(Group B Exclusion 1 4). The physician also has the option to re -schedule the procedure if 
the condition is transient.  
 
12.0 STUDY PROCEDURES  
12.1. Investigator Training   
Investigators will be asked to refer to the drug package insert , device Instructions For Use 
(IFU) and the Investigator’s Brochure  (CIB007001)  for risks related to procedure, drug and 
device . The Investigators  will be trained on use of the I ontophoresis and Tube Delivery 
Systems using a model  system . 
 
12.2. Evaluation Methods  
12.2.1.  Diagnosis  (Group B)  
Eligible subjects will  be indicated for tympanostomy tube placement  in alignment with the  
Clinical Practice Guideline .1  The Clinical Practice Guideline  for tympanostomy tubes in 
children  was developed by a multidisciplinary panel , to provide clinicians with evidence -
based recommendations o n patient selection and surgical indications for and management 
of tympanostomy tubes in children.  
 
In addition to indications aligned with the Clinical Practice Guideline for children, the adult 
subjects in Group B with barotrauma or Eustachian tube dysf unction may also be indicated 
for tube placement per AAO -HNS Clinical Indicators (2010).2Error! Bookmark not defined. 
 
According to the Clinical Practice Guideline, the decisi on to perform  unilateral or bilateral 
tympanostomy tube insertion when unilateral OME is present should be based on caregiver  
preference [to accept or decline the risk of a second surgical procedure] and the likelihood 
of persistent OME developing in the opposite ear. For AOM with presence of effusion, the 
Guideline recommends bilateral TT placement for unilateral or bilateral disease.  With the 
current care paradigm , a physician may perform bilateral tube placement for a unilateral 
condition to avoid the risk of multiple OR procedures and general anesthesia exposures if 
the second ear becomes affected.  Since this  study procedure is conducte d in-office , it is 
proposed that the decision to perform unilateral or bilateral TT placement for AOM with 
effusion  be based on subject  preference and physician clinical judg ment regarding the 
likelihood  of disease developing in the opposite ear, similar t o the Guideline 
recommendation for chronic OME.    
 
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 40 of 70 The indications for tube placement have been clarified (as noted in italics) in instances 
where unilateral placement may be deemed appropriate by the physician and acceptable by 
the subject . The c linical i ndications for tube placement for children include:  
 
• Bilateral TT insertion for b ilateral otitis media with effusion ( OME ) for 3 months or 
longer (chronic OME) and documented hearing difficulties ; 
• Unilateral or bilateral TT insertion for u nilateral or bil ateral OME , respectively,  for 3 
months or longer (chronic OME) and symptoms that are likely attributable to OME 
that include, but are not limited to, vestibular problems, poor school performance, 
behavioral problems, ear discomfor t, or reduced quality of life;  
• Unilateral or bilateral  TT insertion for recurrent acute otitis media ( AOM ) with 
unilateral or bilateral middle ear effusion at the time of assessment for tube candidacy, 
where recurrent AOM is defined as t hree or more AOM episodes in the past 6 months 
or at least 4 AOM  episodes in the past 12 months  with at least 1 in the past 6 months . 
 
In this study, the subject  will be informed of the risk  of subsequent OME or AOM in the 
contralateral ear and the potential need for a second tube inserti on procedure should this 
occur.  Prior to procedure, the Investigator must document which ears are intended for in-
office tube placement.  
 
12.2.2.  Concomitant Medications  
All prior and concomitant medications will be recorded. Prior medications will include all 
prescription and over -the-counter medications taken up to 28 days before procedure. All 
concomitant medications, and changes to medications, will be recorded during each 
subject’s study enrollment period. Medications may be prescribed based on Investigator ’s 
discretion, except for drug s or devices  under investigation through a different protocol .  
 
12.2.3.  Cranial Nerve Physical Exam  
A standard cranial nerve physical exam will be employed at screening , post -procedure  and 
at the follow -up visit to identify any potential adverse effects .  
 
 
 
Any a bnormalities will be recorded at screening and at the follow -up visit and the 
subject will be assessed for any adverse events.   
 
 
12.2.4.  Otoscopy  
An otoscopic exam will be conducted for both ears in all subjects for all study visits .  The  
otoscopic examination will be used to visually examine the condition of the extern al ear 
canal and TM. Routine ear cleaning may be conducted only to the extent necessary to 
ensure the tympanic membrane and ear canal are free from matter that may interfere with  
iontophoretic delivery  and to ensure visualization of the tympanic membrane .  
 
The exam  will be used to confirm eligibility and to assess the ear canal and TM for changes 
or adverse effects. Presence or absence of middle ear e ffusion will  be assessed. In addition, 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 41 of 70 appearance of the myringotomy wound and patency of the tympanostomy tube (Group B 
only)  will be evaluated at the follow -up visit.  Tube functional patency will be determined 
through clinical assessments including otoscopic examination and tympanometry.  
 
The s creening otoscopic exam may be conducted up to 28 days prior to pr ocedure  and will 
be conducted for both ears of all subjects to determine eligibility and ears selected (Group 
A) or indicated (Group B) for treatment . Otoscopic examination is considered standard of 
care for th e Group B  patient population and may be obtained prior to study informed 
consent as a screening assessment within 28 days prior to procedure.  Otoscopic images 
may be collected prior to and following iontophoresis.  
 
12.2.5.  Tympanometry  
Standard t ympanometry  for both ears will be employed to assess TM function at screening 
(within 28 days  prior to procedure) and at the follow -up visit  for all subjects . 
Tympanometry data recorded will include tympanogram type, ear canal volume, peak 
pressure and static acoustic immittance and gradient as an objective measure of tube 
patency and middle ear status .  If adequate tympanometer seal or a valid tympanogram 
cannot be achieved for screening  tympanometry evaluation  (eligible ears for Group A 
subjects and indicated ears for Group B subje cts), the subject will be considered a screening 
failure, and will not be eligible for the study.  Tympanometry is considered standard of care 
for th e Group B  patient population and may be obtained prior to study informed consent as 
a screening assessment w ithin 28 days prior to procedure.   Tympanostomy t ube functional 
patency will be determined through clinical assessments including otoscopic examination 
and tympanometry.  
 
12.2.6.  Audiometry  
Audiometry will be employed  to evaluate hearing statu s and TM function  for both ears at 
screening  (within 28 days  prior to procedure)  and at the post -procedure follow -up visit  for 
all subjects. Threshold testing will be conducted for each ear using air conduction and bone 
conduction at a minimum of 500, 1000,  2000 and 4000 Hz.  
 
Audiometry is considered standard of care for th e Group B  patient population and may be 
obtained prior to study informed consent as a screening assessment within 28 days prior to 
procedure.  
 
12.2.7.  Anesthesia Effectiveness   
Following iontophoresis  for Group A , the Investigator will gentl y tap the TM  once  with a 
standar dized dull otologic instrument . The tap will occur on the anterior half of the TM at 
the location where the tympanostomy tube would theoretically be placed.  The Investigator 
will assess whether the TM is adequately anesthetized for a hypothetical tympanos tomy 
tube placement based on subject response to the TM tap  which is recorded via VAS .   
 
 
 
For Grou p B, the Investigator will inspect the ear canal and TM following iontophoresis . 
and then lightly tap on the anterior half of the TM at the location where the tympanostomy 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 43 of 70  
 
 
 
12.2.10.  Vital Signs  (Group B)  
Vital signs  (diastolic and systolic blood pressure, heart rate,  respiratory rate and  pulse 
oximetry ) measurements will used to evaluate baseline and peri -procedural vital signs to 
assess for any systemic effects of administered drug. Vital signs measurements will be 
recorded 15 minutes and immediately prior to iontophoresis, immediately following 
iontophoresis, following tube placement and at 30 and 60 minutes after completion of 
iontophoresis.  Subjects who experience significant changes in vital si gns (30% or greater 
compare d to baseline) will undergo continued vital sign assessment until the vital sign 
measurements have returned to baseline (ie, beyond the 1 -hour post -procedure evaluation 
period). Additionally, significant changes (30 % or greater c ompared to baseline) will be 
considered adverse events.  
 
12.3. Subject Recruitment and Informed Consent   
For Group B recruitment, c onsecutive potentially -eligible patients  presenting to the study 
site will be offered the opportunity to participate in the study by the investigator. For both 
Groups A and B, s ubject  recruitment will occur through the use of  Sponsor and  IRB-
approved advertisements and information sheets .  
 
The basic objective of the study, the potential benefits and risks of participating, use and 
protection of their personal information, and the option to not participate will be fully 
explained to all prospective subjects as specified in and in compliance with 21CFR §50, the 
Declaration of Helsinki, and  according to the principles of  ISO14155 . The Investigator or 
delegated clinical site r esearch staff will answer all questions to the subject’s satisfaction 
and will allow ample time for the subject  to read the inf ormed consent form and have 
additional questions answered . Subjects will be informed that the trial will be registered in 
the clinical trial registry databank maintained by the National Institutes of Health/National 
Library of Medicine (NIH/NLM) .  All pote ntial subjects  will be  informed through both 
verbal and written information,  and will sign an informed consent , according to local 
requirements , which states that any withdrawal from the study will neither prejudice nor in 
any way affect their future treatment . Subject  consent will be obtained in writing prior to 
any study -related subject data collection or procedures being performed on the subjec t. A 
copy of the completed informed consent form will be given to the subject  and the original 
will be placed in the Investigator’s study record.  
 
If new information that may affect a subject’s willingness to participate or continue in the 
study, the Spon sor will notify the IRB and modify the informed consent  form  as 
appropriate .  
 
All individuals that sign the informed consent will be considered enrolled subjects.  
 
 
 
   

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 44 of 70  
 
 
 
 
 
12.4. Screening Evaluations  
After written informed consent is obtained, the subject is considered enrolled in the study 
and will be screened for inclusion and exclusion criteria .  
  
Screening evaluations may be conducted on day of procedure or at a separate visit up to 28 
days prior to procedure. The Screening Evaluations include  (in any order) : 
 
1. Medical history and concomitant/prior medications  
 
2. Cranial nerve  physic al exam  
 
3. Microscopic otoscopy  with optional ear cleaning  
 
4. Tympanometry  and Audiometry (in either order)  
 
5. Inclusion/Exclusion  
 
12.5.  Procedure  
12.5.1.  Vital Signs (Group B)  
Vital signs (diastolic and systolic blood pressure, heart rate, respiratory rate and pulse 
oximetry) will be monitored 15 minutes and immediately prior to iontophoresis,  and again  
immediately following iontophoresis, following tube placement, 30 minutes and 60 
minutes after completion of ion tophoresis for all Group B subjects.  
 
12.5.2.  Otoscopic Examination and Ear Preparation  
An otoscopic exam will be conducted using a microscope for all ears planned for treatment 
for subjects in Group s A and  B prior to procedure.  The otoscopic examination will be used 
to visually examine the condition of the external ear canal and TM. Routine ear cleaning 
may be conducte d, if needed, only to the extent necessary to ensure the tympanic membrane 
and ear canal are free from matter that may interfere with or influence the evaluation  and 
to ensure visualization of the tympanic membrane . Changes in concomitant medications 
will be recorded.  
 
12.5.3.  Earset Sizing  
The IPS Earset  is available in  6 sizes . The ear sizing procedure will be performed according 
to the Instructions for Use (IFU) provided with the IPS. If the subject’ s ear is not compatible 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 45 of 70 with th e ear plug and fit cannot be established to ensure the earplug can properly seal in the 
ear canal, the subject will  be considered a screen ing failure. 
 
12.5.4.  Anesthetic Solution Preparation  
Ten ( 10) mL of 2% lidocaine /1:100,000 epinephrine  anesthetic solution will be warmed to 
body temperature prior to instillation in the ear canal to minimize the caloric effect.  
 
12.5.5.  Earset  Placement and Drug Instillation  
Baseline tolerability will be assessed before placement of the Earset. The Earset ear plug 
of the size determined in the ear sizing procedure is then placed into the ear canal . Once 
the ear plug is positioned, the pro tective liner is removed, exposing the PSA to the ear canal. 
Circumferential pressure is applied through the ear plug against the surface of the ear canal,  
ensuring adhesion of the PSA. The Earset’s integrated fill system is used to instill the 
selected dr ug into the ear canal. This process is repeated  for the second ear , as applicable .  
 
The Electrode  Cable is snapped to the Return Electrode Patch.  The Return Electrode Patch 
is then attached to the patient at a clean, dry site (such as the  shoulder near th e base of the 
neck ) that is clear of lesions, bony protuberances and excessive hair. Prior to placing the 
return electrode on the patient, the investigator will assess the location for pre -existing 
erythema using the five point Draize erythema score where 0 indicates no erythema, 1 = 
very slight erythema (barely perceptible), 2 = well -defined erythema, 3= moderate to severe 
erythema, 4= severe erythema to slight eschar formation.43 The location will be assessed 
again following iontophoresis.  
 
12.5.6.  Start of Iontophoresis  
To begin anesthesia, the applicable Control Unit button (s) are pressed to initiate current. 
Initiation of current represents the beginning of the iontophoresis procedure. There are two 
buttons, one for each ear . Without interruptions, the Con trol Unit operation will take 
approximately 10 minutes . Progress through the iontophoresis cycle can be monitored via 
the status bars on the Control Unit which fill to indicate progress toward completion.  
 
The procedure can be paused at any time, and then  resumed. The Control Unit will account 
for these pauses to ensure consistent current dose delivery, and will provide a visible and 
audible signal when complete.  
 
For Group A subjects  randomized to  sham iontophoresis , all procedures will take place as 
described above .  The iontophoresis unit will not be activated, as dictated by the 
randomization schedule.   
 
 
 
 
 
  
  
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 46 of 70   
 
  
 
 
  
 
  
 
 
 
   
 
 
 
 
 
 
 
12.5.7.  Anesthetic Solution and Return Electrode Patch Removal  
At the e nd of iontophoresis , the Earset(s) , and Return Electrode  Patch are removed and the 
anesthetic solution is removed fr om the ear canal either by wick or  head  tilting.  
 
The return electrode location will be assessed by the treating physician upon completion of 
iontophoresis and removal of the return electrode patch. Observations will be graded using 
the five point Draize erythema score where 0 indicates no erythema, 1 = v ery slight 
erythema (barely perceptible), 2 = well -defined erythema, 3= moderate to severe erythema, 
4= severe erythema to slight eschar formation.44 Scores of 3 or greater will be considered 
adverse events.  
 
12.5.8.  Post-Iontophoresis Anesthesia Effectiveness  (Gro up A)  
Following iontophoresis, the Investigator will inspect the ear canal and TM using the 
microscope. The Investigator will then lightly tap on the anterior half of the TM  to elicit 
subject sensation  (at the location where a tympanostomy tube w ould theor etically  be 
placed) which is recorded via VAS .   
 
 
 
   
 
 
 
If an unexpected serious complication occurs  during the procedure , the procedure will be 
terminated. T he Investigator will take all appropriate intra - and post -treatment measures to 
ensure subject sa fety and proper treatment . The Investigator will notify Tusker Medical  and 
their IRB immediately, but in no instances greater than 24 hours of the incident .  
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 47 of 70 12.5.9.  Post-Iontophoresis Anesthesia Effectiveness (Group B)  
Following iontophoresis, the Investigator will inspect the ear canal and TM using the 
microscope. The Investigator will then lightly tap on the anterior half o f the TM at the 
location where the  tympanostomy tube will be placed to elicit subject sensation which is 
recorded via VAS  for each ear.  
 
 
The Investigator will assess whether the TM is adequately anesthetized for the 
tympanostomy  tube placement based on subject response to the TM tap for each ear.   This 
tap assessment method has been used successfully in prior studies to determine adequate 
anesthesia for subsequent tympanostomy tube placement for both children and adults.  
 
12.5.10.  Tympanostomy Tube Placement  (Group B  only) 
In at least one ear, t he Investigator will place the TT using the TDS while the subject’s head 
is gently stabilized by the clinic s taff, as is typical for standard of care ear examinations. If 
the TT is not successfully placed by the TDS device, the investigator may choose to attempt 
tube placement with another TDS device .  
 
 
 
 
  
 
Following TDS tube placement, the subject will report their post -tube placement ear 
discomfort for each ear  underg oing tube placement using the VAS .  For bilateral tube 
placement subjects, the ‘worst’ ear pain score (highest score) will be used for analysis of 
the tube placement tolerability primary endpoint.   
 
 
 
 
 
 
 
  The subject’s VAS score for each ear following suction 
will be recorded. Post-operative care , including otic drops,  will be prescribed per 
investigator’s discretion. All post -operative medications will be documented.  
 
If an unexpected serious complication occurs  during the procedure , the procedure will be 
terminated. T he Investigator will take all appropriate intra - and post -treatment measures to 
ensure subject safety and proper treatment . The Investigator will notify Tusker Medical  and 
their IRB immediately, but in no instances greater than 24 hours of the incident .  
 
12.5.11.  Cranial Nerve Exam  
The cranial nerve physical exam will be conducted  post-procedure . 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 48 of 70 12.6. Group A Follow -up 
Follow -Up Visit at 3 Days Post -Proced ure ( -1/+2 Days)  
 
1. All subjects are required to return for the 3 -day post -procedure follow -up visit.  
 
2. A microscopic otoscopic examination will be used to visually examine the condition of 
the external ear canal and TM. If any adverse otoscopic findings are observed, 
microscopic images will be collected for each ear.  
 
3. The subject will complete audiometry and tympanometry, and cranial nerve  physical 
exam.  
 
4. The ears will be evaluated for any adverse events .  
 
5. If there are suspected procedure, device or drug -related adverse findings, the subject is 
required to return for follow -up at 12 ± 3 days po st-procedure.  
 
6. If there are no unresolved suspected procedure, device or drug -related adverse findings, 
the subject will then be exited from the study.  
 
7. Follow -up for other adverse events will be determined according to Investigator 
discretion.  
 
Follow -Up Visit at 12 Days Post -Procedure ( ±3 Days)  
 
1. Only subjects with suspected procedure, device or drug -related adverse events  that are 
not resolve d at the 3 -day visit, or per Investigator decision, are required to complete the 
12 days post -procedure follow -up visit. 
 
2. A microscopic otoscopic examination will be used to visually examine the condition of 
the external ear canal and TM. If any adverse otoscopic findings are observed, 
microscopic o toscopic images will be collected for each ear.  
 
3. The ears will be evalu ated for any new or ongoing adverse events.  
 
4. The subject will complete audiometry and tympanometry, and cranial nerve  physical 
exam.  
 
5. The subject will then be exited from the study.  
 
12.7. Group B Follow -up 
3-Week Post -Procedure Follow -Up Visit (+/ - 7 Days)  
 
1. All subjects are required to return for the 3-week  post-procedure follow -up visit.  
 
2. An otoscopic examination will be used to visually examine the condition of the external 
ear canal , TM , myringotomy  wound and tube patency.  
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 51 of 70 which cannot be attributed to natural history or progression of the disease. This definition 
does not depend on the causal relationship with the device , drug  or protocol requirements.  
 
Any change of clinical significance , including vertigo, nausea and vomiting,  derived from 
the protocol evaluations including observations and patient -reported findings will be 
included as adverse events.  Changes in vital s igns 30% or greater compared to baseline will 
be considered adverse events.  
 
All Adverse Events (AEs) will be recorded on dedicated AE case report forms . The event, 
date of onset, severity, seriousness, duration, treatment, outcome , date or resolution  and 
relationship to device, procedure or drug will be recorded on the AE case report form 
(CRF ). AEs will be categorized by seriousness, relatedness to procedure, investigational 
drug, or device whether anticipated or unanticipated . All adverse events will be coded using 
standard terms.  
 
13.2. Serious Adverse Events  
If an unexpected serious complication resulting in an adverse event occurs during the 
procedure, the  procedure will be terminated . The Investigator will take all appropriate intra - 
and post -procedural measures to ensure subject safety and proper treatment. In the event of 
a serious adverse event  at any time during the study , the Investigator will notify the Sponsor 
and their IRB immediately or no later than within 24 hours.  
 
All Serious Adverse Events  that have not resolved by the end of the subject's participation 
in the study must be followed until  the event resolves, improves, or stabilizes. The 
investigator should report any follow -up information as it becomes a vailable.  
 
13.3. Adverse Event Definitions   
Adverse Event (AE)  
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated 
with the procedure or use of the device or investigational drug, and does not imply judgment 
about causality.  
 
Serious Adverse Event (SAE)  
AEs are classified as serious or non -serious . A serious adverse event is any AE that is:  
 
• Fatal  
 
• Life-threatening  
 
• Requires or prolongs hospital stay  
 
• Results in persistent or significant incapacity  or substantial disruption of the ability to 
conduct normal life functions  
 
• Led to fetal distress, fetal death or congenital abnormality or birth defect  
 
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 52 of 70 • An important medical event that may jeopardize the subject, and may require medical 
or surgical interv ention to prevent one of the other serious outcomes noted above .  
 
Life Threatening Adverse Event or Life -Threate ning Suspected Adverse Reaction  
An adverse event or suspected adverse reaction  is considered life threatening  if, in the view 
of either the inv estigator or sponsor, its occurrence places the subject at immediate risk of 
death. It does not include an adverse event that, had it occurred in a more severe form, 
might have caused death.  
 
Unanticipat ed Adverse Device Effect (UADE)  
A UADE  is any serious  adverse effect on health or safety or any life -threatening problem 
or death caused by, or associated with, a device, if that effect, problem or death was not 
previously identified in nature, severity, or degree of incidence in the investigational plan 
or application, or any other unanticipated serious problem associated with a device that 
relates to the rights, safety, or welfare of subjects.  
 
In order to ensure subject safety during the study, all adverse events assessed as “serious” 
in the opinion of th e Investigator will be reviewed by the Medical Monitor to determine 
any causal relationship to the study drug, device  or procedure. All adverse events that do 
not meet any of the criteria for serious should be regarded as non -serious adverse events. 
Non-serious adverse events must still be documented on the appropriate CRF.  
 
Reporting  
The sponsor will notify FDA , all reviewing IRBs  and all participating Investigators of 
potential serious risks, from this study or any other source, as soon as possible, but i n no 
case later than 15 calendar days after the Sponsor determines that the information qualifies 
for reporting, including : 
 
1. Suspected adverse drug reactions that are considered both serious and unexpected,  
 
2. Findings from other studies that suggest a significant risk in humans exposed to the 
drug,  
 
3. Findings from animal or in vitro testing that suggest a significant risk in humans 
exposed to the drug, and  
 
4. An increased rate of occurrence of serious suspected adverse reactions.  
 
In addition, the sponsor  will notify  FDA , all reviewing IRBs and participating investigators 
within 10 working days after the S ponsor first receives notice of an Unanticipated Adverse 
Device Effect .  
 
13.4. Adverse Event Classificat ion  
Adverse Event Severity   
All adverse events will be classified as to the severity of the event  based on the definitions 
consistent with AE severity  grading  scale  provided by the National Cancer Institute, of the 
NIH and US Department of Health and Huma n Services – Common Terminology Criteria 
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 55 of 70 durin g preparation during procedure), nature of the malfunction and relatedness to potential 
adverse events will be collected on appropriate CRFs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14.0  STATISTICAL METHODS   
This study will consist of two independent Groups, referred to as Group A and Group B.  
Each group has its own primary endpoint, each of which must pass the statistical test for 
the overall study to be considered successful.  
 
Group A will consist of 40 healthy adult subjects aged 18-50, enrolled at two 
investigational centers in the  US. Group A subjects will be  randomized to receive 
unilateral (1 ear) active lidocaine iontophoresis or unilateral sham lidocaine iontophoresis.  
The sham iontophoresis procedure will be identical to the active lidocaine iontophoresis, 
with the exception that the iontophoresis channel will not be activated  (ie, the same drug 
solution will be applied to both ears).  After the completion of the iontophoresis, the 
tympanic membrane will be tapped with a dull otologic probe to test anesthesia  
effectiveness . The subject will rate the level of pain using the VAS after the ear is tapped.   
 
Group B will consist of 30 adults  age 18  years  or older  who require unilateral or bilateral 
tube insertion, enrolled at up to 9 centers in the US.  Group B subjects will receive active 
lidocaine iontophoresis and tube insertion  using the TDS in all ears that require tube 
insertion.  The subject will rate the pain on tube insertion using the VAS , and the pain 
score will be  compared to a fixed performance goal.  
 
14.1. Subject Disposition   
The number and proportion of subjects in Groups  A & B eligible for and compliant with 
all follow -up examinations will be presented. Subjects who withdraw from the study will 
be tabulated with the reasons for the withdrawal. Subjects who initiate the procedure, 
regardless of tolerability outcome or anest hesia effectiveness, will be encouraged to 
return for all follow -up assessments.  
 
14.2. General Statistical Methods  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 56 of 70 Descriptive statistics will be provided . Data collected in the study will be summarized 
overall and as defined in the protocol .  
 
Routine presentation of continuous variables in descriptive tables will include mean, 
standard deviation, sample size, and median . Categorical or binary variables will  be 
presented with numerator, denominator, and percent .  
 
The SAS system (v9. 2 or later) or R will be used to perform all statistical analyses.  
 
14.3. Group A  – Statistical Methods  
14.3.1.  Randomization & Blinding  
Subjects  will be randomized (1:1) to either active lidocaine  iontophoresis  or sham 
lidocaine iontophoresis . Randomization will be stratified by site  and will be  balanced 
by using permuted blocks.  
 
  
 
The study will be double -blinded such that the Investigator and subjects will be blinded 
to treatment assignment to minimize bias regarding Investigator and Subject -reported 
outcomes.  
 
 
 
 
 
 
 
  
 
  
  
  
 
  
 
  
 
 
  
 
 
 
 
 
 
 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 57 of 70  
 
 
 
 
  
 
 
 
 
 
14.3.2.  Analysis Sets 
14.3.2.1.  Modified Intention to Treat (mITT)  
The mITT analysis set includes a ll subjects who are randomized and in whom the 
lidocaine is introduced into the ear canal . Subjects who discontinue  iontophoresis 
prior to t he TM tap assessme nt or decline TM tap assessment  will provide a pain 
score for the attempted procedure and will be included in the mITT . Only subjects 
who do not complete the procedure due to reasons not related to iontophoresis 
discomfort (eg, anatomy not compatible with device fit) will be excluded . 
Subjects will be analyzed as randomized.  
 
14.3.2.2.  Per Protocol Set  
The Per Protocol Set is a subset of the mITT  and includes all mITT  subjects 
without major protocol deviations.  Major protocol deviations include:  
• Eligibility violations  
• Procedural deviations with the potential to affect anesthesia efficacy (eg, 
abbreviatio n of iontophoresis or use of incorrect local anesthesia drug).  
 
14.3.2.3.  Safety  Analysis Set 
The Safety Analysis Set will include a ll subjects  in whom the lidocaine solution 
is introduced into the ear canal  (same as the mITT set).  
 
14.3.3.  Primary Endpoint Analysis  
Group A  subjects are randomized to either active lidocaine iontophoresis or sham 
lidocaine iontophoresis. Each subject will have a VAS  score.   
 
The null and alternative hypotheses are:   
 
Ho :  µT- µS= 0 
vs. 
H1 : µT- µS < 0 
 
where µT and µ S are the mean scores in the treatment and sham arms respectively . 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 58 of 70 The primary endpoint will be evaluated in the mITT set using a permutation test  at a 
2.5% significance level. The primary endpoint will be demonstrated if the p-value from 
the permutation test is less than or equal to 0.025 .   
 
14.3.4.  Safety Analysis  
All reported or observed adverse events that occur for subjects in the Safety Analysis 
Set during or after the procedure will be recorded. All AEs will be tabulated by 
treatment group. AEs will be summarized by preferred terms and system organ class 
using the Medical Dictionary for Regulatory Activities (MedRA). The frequency of 
each event will be summarized by seriousness, severity and by relationship to the study 
device, procedure and /or drug.  Separate summaries will be provided for SAEs and AEs 
related to study device, procedure and/or drug. In the event a subject reports the same 
event severa l times (eg, otalgia), the first occurrence of the worst reported case of the 
event will be used for the purpose of analysis.   
 
 
 
  
  
  
  
  
 
  
 
 
 
 
  
 
  
 
 
 
  
 
14.4. Group B  – Statistical Methods  
14.4.1.  Analysis Sets  
14.4.1.1.  Full Analysis Set (FAS)  
The FAS includes all subjects in whom the lidocaine solution is introduced into the 
ear canal.   
 
14.4.1.2.  Per Protocol Set  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 59 of 70 The Per Protocol Set is a subset of the FAS and includes FAS subjects without maj or 
protocol deviations.  Major protocol deviations include:  
• Eligibility violations  
• Procedural deviations with the potential to affect anesthesia efficacy (eg, 
abbreviation of iontophoresis or use of incorrect local anesthesia drug).  
 
14.4.1.3.  Safety  Analysis Set  
The Safety Analysis Set will include a ll subjects  in whom the lidocaine solution is  
introduced into the ear canal (same as FAS).  
 
14.4.2.  Primary Endpoint Analysis  
Group B subjects will each have a VAS  score that captures the pain associated with 
tube insertion . 
 
The null and alternative hypotheses are:  
 
H0: µ ≥ 4. 5 
H1: µ < 4. 5 
 
where µ is the mean VAS  score across subjects.  
 
The primary endpoint will be evaluated in the Per Protocol set using the bootstrap 
method at a 2.5% significance level. The primary endpoint will be demonstrated if the 
upper confidence bound of a 95% non-parametric bootstrap confidence interval on the 
mean score is below 4.5.  For bilateral subjects the highest score (‘worst ear’) will be 
used as the subject score . If a subject is intended for unilateral treatment , then the score 
from only the treated ear is collected and  included in the analysis. The prim ary analysis 
for Group B will  be performed based on complete rs in the P er Protocol  set, specifically 
including only subject s with  VAS scores following successful tube insertion  for all ears 
indicated for treatment (both ears for bilateral subjects and one ear for unilateral 
subjects) .  
 
 
  
 
14.4.3.  Safety Analysis  
All reported or observed adverse events that occur for subjects in the Safety Analysis 
Set d uring or after the procedure will be recorded. All AEs will be tabulated . AEs will 
be summarized by preferred terms and system organ class using the Medical Dictionary 
for Regulatory Activities (MedRA). The frequency of each event will be summarized 
by ser iousness, severity and by relationship to the study device, procedure and /or drug.  
Separate summaries will be provided for SAEs and AEs related to study device, 
procedure and/or drug. In the event a subject reports the same event several times (eg, 
otalgia ), the first occurrence of the worst reported case of the event will be used for the 
purpose of analysis.   
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 60 of 70  
 
  
  
  
  
  
 
  
 
 
 
 
  
 
  
 
 
 
 
 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 61 of 70  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 62 of 70  
 
 
 
 
 
 
 
 
  
 
14.6. Handling Drop Outs or Missing Data  
Group A Primary Endpoint: If a subject in Group A discontinues iontophoresis  prior to 
the TM tap assessment or declines TM tap assessments, the subject will provide a VAS 
pain score for the attempted procedure and will be included in the analysis of the 
primary endpoint.  
 
 
 Reasons for discontinuation will be 
documented and presented in the clinical study report.   
 
Group B Primary Endpoint: If a subject in Group B discontinues iontophoresis or tube 
placement, the subject will provide a VAS pain score for the attempted procedure . 
Subjects with d iscontinued procedures will be included in  the sensitivity analyses  only, 
and will not be included in  the primary analysis. Only subjects with scores after tubes 
are successfully placed in all indicated ears (one tube if indicated for unilateral 
treatment and two tubes if indicated for bilateral treatment) will be included in the 
primary analysis.   
 
 
 
 
 
 Reasons for discontinuation will be documented and presented in 
the clinical study report.  
 
 
 
 
 
 
 
14.7. Multiplicity  Adjustment  
Group s A & B each have  a single primary endpoint tested at a significance level of 
2.5% .  Each primary endpoint must pass the statistical test for the study to be considered 
successful.  The familywise error rate is therefore controlled at 2.5% and no mult iplicity 
adjustments are planned.  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 63 of 70  
 
 
 
15.0 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
Prior to enrolling subjects, all sites must have the approval of an Institutional Review Board 
(IRB) responsible for reviewing clinical studies at the study site . The IRB must also 
approve the subject Informed Consent  as well as recruiting advertisements and subject -
facing information . Amendments to any of these documents must also be approved by the 
IRB. No subjects will be consented or enrolled to a site until IRB approval has been 
received in writing.  The Informed Consent process is described in Section 12.3.  
 
15.1. Subject Confidentiality  
Subject confidentiality will be maintained at all times during the study . A unique subject 
identifier will consist of ( 1) a Protocol Identifier, (2) an Investigational Site identifier , and 
(3) a consecutive subject number  with designated group assignment (A or B) .  
 
Example: 7003-JON-A01 in Group A  
 
7003 = 4 digit Protocol Number  
 
JON = Investigator Dr . Jones  
 
A01 = Number of subject enrolled  
 
The Investigator or evaluation personnel at each study site will assign the subject identifier  
and access to this identifier  will be restricted to the Investigator and evaluation personnel . 
The key to the subject identifier  and subject data collection sheets containing the subject’s 
name and identification code will be securely maintained at each study site.  
 
 
16.0 PREMATURE TERMINATIO N OR WITHDRAWAL  
16.1. Subject Stopping Criteria  
Subjects who do not  complete the study procedure will be en couraged to remain in the 
study to complete post -procedure evaluations. If a subject withdraws prematurely from the 
study, a genuine effort must be made to determine the reason(s) why the subject failed to 
return for the procedure or follow -up visit or dis continued the study, and the reason must 
be recorded on the appropriate CRF.  
 
Potential reasons for discontinuation include:  
 
• Subject  decides it is in their best interest  to withdraw  
 
• Subject expresses  intole rable discomfort during the procedure and  indicate s they 
wish to stop the procedure and withdraw  
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 64 of 70   
• Serious  adverse event that requires withdrawal from the study  
 
• Investigator decides it is in the subject’s best interest to be withdrawn if subject is 
experiencing  intolerance or intolerable reaction to the procedure.  
 
If the subject wishes to discontinue participation in the study, the Investigator will attempt 
to have the subject continue participation to complete follow -up assessments unless the 
subject’s safety  is compromised.  All Serious Adverse Events that have not resolved by the 
end of the subject's participation in the study, must be followed until the event resolves, 
stabilizes or becomes non -serious.  
 
All potential subjects in the study will be verbally  informed and will sign an informed 
consent in compliance with 21CFR §50 that states that any withdrawal from the study will 
neither prejudice nor in any way affect their future treatment.  
 
Prior to designating a subject as lost to follow -up, the site must  provide documented 
evidence of three (3) good faith attempts to contact the s ubject to which there has been no 
response . At that point the s ubject will be considered lost -to-follow -up and withdrawn from 
the study.  
 
   
 
 
 
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
 
 
  
 
 
  
 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 65 of 70  
 
  
 
 
 
 
 
  
 
  
 
   
  
  
 
 
 
 
 
17.0 INVESTIGATOR RESPONSIBILIT IES 
Investigators who participa te in this study will conduct the study according to the protocol, 
the Declaration of Helsinki, GCP and applicable regulatory requirements.  Tusker Medical  
will sponsor the conduct of  the study at up to 8  investigational centers . This study will be 
performed under the  direction and responsibility of the physician investigator at each study 
site. It is the responsibility of the Investigators to ensure study materia l is reviewed and 
approved by all applicable Institutional Review Boards (IRB), hospital committees, and 
administrative personnel as required .  
 
The Investigator is responsible for the execution of the study, proper performance of 
participating personnel, ensuring adherence to the protocol and schedule of procedures , and 
for the control of devices under investigation . The Investigator is also responsible for 
protecting the rights, safety, and welfare of subjects under the investigator's care, and 
ensuring t hat written informed consent is obtained.  
 
The Investigator is responsible for data confidentiality, quality, and completeness, and 
proper data storage in a secure file for a period of time as indicated in the protocol, Clinical 
Trial Agreement (CTA) and if mandated, by the respective IRBs.  
 
The Investigator and site personnel directly involved with the study will receive training in 
the protocol and use of devices prior to initiation of the study . This training will be 
conducted by the Sponsor ( Tusker Medical , Inc.) or designee, prior to initiation of the 
study .  
 
18.0 SPONSOR  

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 66 of 70 Tusker Medical , Inc. is the device manufacturer as well as the study sponsor (“Sponsor”). 
The Sponsor will work with the study site under the terms of the Clinical Trial Agreement 
(CTA) .  
 
The Sponsor contact is as follows:  
 
Tusker Medical , Inc.  
155 Jefferson  Drive , Suite 200  
Menlo Park, CA 94025  
 
 
 
 
  
 
 
19.0  MONITORING  
Tusker Medical , Inc. (Sponsor) or designee will monitor the study sites to ensure 
investigators are in compliance  with the protocol; subject informed conse nt forms are 
properly completed;  adequate protection of the rights of the human subjects and the quality 
and integrity of the resulting data ; study data is verified against source documents for  key 
safety and effectiveness variables ; investigational devices  and drug  are properly controll ed; 
and verification that reports are filed in accordance with the protocol a nd the appropriate 
regulations.  Monitoring will be conducted according to the Sponsor’s monitoring 
procedure and study monitoring plan.  
 
20.0 INVESTIGATIONAL PROD UCT ACCOUNTABILITY  
Access to investigational drug and devices shall be controlled and the investigational drug 
and devices shall be used only in the clinical invest igation and according to the protocol . 
The Sponsor shall keep records to document the physical location of all inv estigational 
drug and devices from shipment to the investigation sites until return or disposal . Drug and 
devices will be stored according to product labeling. The principal investigator or an 
authorized designee shall keep records documenting the receipt,  use, return, and disposal 
of the investigational drug and devices, which shall include (a) the date of receipt, (b) 
identification of each investigational drug and device (batch number/serial number or 
unique code), (c) the expiration date, (d) the date o r dates of use, (e) subject identification, 
and (f) the date of return of unused, expired or malfunctioning investigational products , if 
applicable.  
 
21.0 DEVIATIONS  
A protocol deviation is defined as any event where the Investigator or site personnel deviate 
from the study protocol or study procedures for any reason . It is the Investigator’s 
responsibility to ensure that there are no protocol deviations throughout the life of the study . 
In the event that a non -emergency protocol deviation is identified , at the time of 
identification, the personnel identifying the event will review and define appropriate 

Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 67 of 70 corrective actions to prevent recurrence . The IRB will be notified as applicable.  Any 
deviations from this protocol will be documented by the site on a protocol deviation CRF .  
 
 
 
22.0  DATA HANDLING AND R ECORD KEEPING  
22.1. Source Data and Case Report Forms  
 
All study data will be captured on source documents by the Investigational Site . Data 
from the source documents will be recorded to CRFs  by site personnel tha t have been 
trained on the protocol and CRF completion .  
 
22.2. Data Quality Assurance  
Accuracy and reliability of the clinical study data will be  ensured  by selection of 
qualified investigators, and appropriate study centers, review of protocol procedures 
with the investigators and associated personnel prior to the study, and by periodic 
monitoring visits by the sponsor. CRFs will be  reviewed for accuracy and completeness 
by the sponsor during on site monitoring visits and after their return to the sponsor, and 
any discrepancies w ill be  resolved with the investigator or designees, as appropriate.  
 
22.3. Record Retention  
All clinical sites will maintain all records pertaining to this study for a minimum of two 
years after marketing approval or formal discontinuation of investigational product 
developmen t. The Sponsor will notify the clinical sites of the date of discontinuation. 
No study -related records, written or electronic, will be destroyed or transferred without 
specific written approval by the Sponsor.  
 
23.0  PUBLICATION POLICY  
The CTA mutually signed b y the Investigator(s) and Tusker Medical , Inc., defines and 
describes the nature of the study agreement.  
 
The Sponsor retains the rights to this protocol  and the CRFs before and after data entry. 
Tusker Medical , Inc. reserves the right to review any report s of this study to verify that the 
information is accurate and to ensure the content and timing of any such publication is 
mutually agreed upon by the Investigator(s) and Tusker Medical , Inc . Draft abstracts, 
manuscripts, and materials for presentation at scientific meetings should be provided to the 
sponsor at least 30 working days prior to submission.  
 
Clinical trial information will be registered in the clinical trial registry databank maintained 
by the National Institutes of Health/National Library of M edicine (NIH/NLM)  per FDAAA 
801 requirements . If a future publication results from this study, a uthorship will be 
established according to ICMJE guidelines.  
 
  
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 68 of 70  
24.0  REFERENCES  
1 Rosenfeld RM, Schwartz SR, Pynnonen MA, Tunkel DE, Hussey HM, Fichera JS, Grimes 
AM et al. Clinical pr actice guideline: tympanostomy tubes in children. Otolaryngol Head 
Neck Surg, 2013; 149(IS):S1 -S35. 
2 AAO -HNS Clinical Indicators, 2010 : 
https://www.societyformiddleeardisease.org/Content/ClinicalIndicators/Myringotomy -and-
Tympanostomy -Tubes -CI.pdf . Accessed on 02 July 2016.  
3 Otitis Media (Ear Infection), NIDCD, July 2002. NIH Pub No. 97 -4216. 7 Aug 2008 
http://www.nidcd.nih.gov/health/hearing/  otitism.asp.  
4 Klein J, Pelton S. Epidemiology, pathogenesis, clinical manifestations, and complica tions of 
acute otitis media.  Up to Date, October 2008, 7 Aug 2008.  
5 Tusker Medical analysis of Truven Commercial, Medicaid and Medicare databases.  
6 Litman RS. Basics of Pediatric Anesthesia. Philadelphia, PA, 2013.  
7 Dewhirst E, Fedel G, Raman V et al. Pain management following myringotomy and tube 
placement: Intran asal dexmedet omidine versus intran asal fentanyl. Int J Pediatr 
Otorhinolaryngol , 2014; 78(7):1090 -1094 . 
8 Montague ML, Lee MSW, Hussain SSM. Human error identification: an analysis of 
myringotomy and ventilation tube insertion. Arch Otolaryngol Head Neck Surg, 
2004;130 :1153 -1157.  
9 Isaacson G. Six s igma tympanostomy tube insertion: a chieving the highest safety lev els 
during residency training. Otolaryngol Head Neck Surgery, 2008; 139:353 -357. 
10 Kesser BW, Derebery MJ, Friedman RA. (2010) Surgery of ventilation and mucos al 
disease. In: Otologic Surgery. Brackmann DE, ed. Pages 73 - 91 (Philadelphia, PA: Saunders, 
2010).  
11 Freeman SRM, Iseli CE, Kerr MBA, Kong JHK, Gibson WPR . Phenol application for 
tympanic membrane anesthesia. Clin Otolaryngol , 2007; 33:152 -199. 
12 EMLA dr ug label; 
http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?ar chiveid=1240, accessed 
03June2016.  
13 Jyvakorpi M. A comparison of topical EMLA cream with Bonain’s solution for anesthesia 
of the tympanic membrane during tympanocentesis. Eur Arch Otorhinolaryngol , 1996; 253: 
234-236. 
14 Todd N. What your colleagues think of tympanostomy tubes 28 years later. Laryngoscope , 
1999; 109:1028 -1032.  
15 Markowitz -Spence L, Brodsky L, Syed N, Stanievich J, Vold M. Anesthetic complica tions 
of tympanostomy tube placement in children. Arch Otolaryngol Head Neck Surg, 2006; 116: 
809-812. 
16 Hoffmann  KK, T hompson GK, Burke BL, Derkay CS. Anesthetic complications of 
tympanostomy tube placement in children. Arch Otolaryngol Head Neck Surg , 2002; 128: 
1040 -1043.  
17 Ing C,  Dimaggio C, Whitehouse A et al.  Long -term differences in language and cognitive 
function after childhood exposure to anesthesia. Pediatrics , 2012; 130: e476.  
18 Wild er RT, Flick RP, Sprung J et al.  Early exposure to anesthesia a nd learning disabilities 
in a population - based birth cohort. Anesthesiology , 2009; 110: 796.                                                   
Tusker Medical , Inc.      Confidential  
CPR00 7003  Rev C 
Effective:  05/02/2017   Page 70 of 70                                                                                                                                                         
39 Jensen MP, Chen C, Brugg er AM. Interpretation of visual analog scale ratings and change 
scores: a reanalysis of two clinical trials of postoperative pain. J Pain, 2003; 4(7):407 -414.  
40 Rosenfeld RM, Schwartz SR, Pynnonen MA, Tunkel DE, Hussey HM, Fichera JS, Grimes 
AM et al. Clinical practice guideline: tympanostomy tubes in children. Otolaryngol Head 
Neck Surg, 2013; 149(IS):S1 -S35. 
41 AAO -HNS Clinical Indicators, 2010 : 
https://www.societyformiddleeardisease.org/Content/ClinicalIndicators/Myringotomy -and-
Tympanostomy -Tubes -CI.pdf . Accessed on 02 July 2016.  
42 http:www.amda.com/tools/library/whitepapers/hopsiceinltc/appendix -a.pdf. Accessed on 09 
Feb 2017.  
43 Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of 
substances applied topically to the skin and mucous membranes. J. Phar macol. Exp. 
Therapeutics, 1944; 82: 377 –390.  
44 Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of 
substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. 
Therapeutics, 1944; 82: 377 –390.  
45 US Department of Health and Human Services, NIH, National Cancer Institute, “Common 
Terminology Criteria for Adverse Events (CTCAE), NIH Publication No 09 -5410, Version 
4.03, June 14, 2010.  
46  The use of the WHO –UMC system for standardized case causality assessm ent. Accessed 
from: http://WHO -UMC.org/graphics/24734.pdf . accessed on 29  May 2016 . 
47 Clark JG: Uses and abuses of hearing loss classification.  ASHA,  1981 ; 23(7):493 – 500. 
48 American Academy of Audiology Childhood Hearing Screening Guidelines, Sept 2011. 
Accessed from: http://www.cdc.gov/ncbddd/hearingloss/document s/AAA_Childhood 
%20Hearing%20Guidelines_2011.pdf . accessed on 29 May 2016.  
  
 
